Chronic Kidney Disease (CKD) in Children — Risks, Complications, and What to Watch For

 

Short overview: Chronic kidney disease (CKD) in children is different from adult CKD in its causes, course, and the kinds of harm it produces. While adults most commonly develop CKD from diabetes and hypertension, children more often have congenital or developmental kidney problems. Yet children with CKD face serious, lifelong risks — not only loss of kidney function and progression to end-stage kidney disease (ESKD), but also stunted growth, bone disease, severe anemia, cardiovascular disease, neurocognitive and psychosocial impairments, and higher infection risk. Early recognition, careful monitoring, and multidisciplinary care dramatically alter outcomes. Below is a detailed, evidence-based article on the major risk issues tied to pediatric CKD and practical implications for clinicians, families and policy makers. (Key guideline and review sources cited throughout.)

 

 

---

 

1. What we mean by CKD in children

 

CKD is defined as abnormalities of kidney structure or function present for ≥3 months with implications for health (reduced glomerular filtration rate (GFR), albuminuria, or structural abnormalities). In children the staging (G1–G5) is similar to adults, but the consequences differ because kidneys and the child’s body are still growing. The most recent KDIGO guidance and pediatric reviews highlight the need for growth- and development-focused assessment in children. 

 

 

---

 

2. Epidemiology — who gets pediatric CKD?

 

Major causes: Congenital anomalies of the kidney and urinary tract (CAKUT) are the leading cause globally (including renal dysplasia, hypoplasia, posterior urethral valves, obstructive uropathy). Glomerular diseases (e.g., focal segmental glomerulosclerosis, hereditary nephropathies) and hereditary/genetic disorders also contribute. In adolescents, diabetes (type 1, and increasingly type 2) and acquired glomerulonephritis are more prominent. 

 

Geography and inequity: Incidence and outcomes vary widely by country — low- and middle-income countries (LMICs) face later diagnosis, limited access to dialysis/transplant, and worse outcomes. Socioeconomic factors, prenatal care, and access to pediatric nephrology influence prevalence and progression. 

 

 

 

---

 

3. Risk factors for developing CKD (causal and predisposing)

 

Understanding these helps prevention and early detection.

 

Prenatal & perinatal factors

 

Low nephron number from prematurity, intrauterine growth restriction, or congenital anomalies reduces renal reserve and increases lifetime CKD risk. Perinatal complications (sepsis, neonatal acute kidney injury, exposure to nephrotoxic drugs) are important contributors. 

 

 

Congenital structural and genetic causes

 

CAKUT, renal dysplasia, and monogenic kidney diseases (e.g., cystic kidney diseases, congenital nephrotic syndromes) are major pediatric contributors. Genetic testing increasingly identifies etiologies and prognosis. 

 

 

Acquired causes

 

Recurrent urinary tract infections with scarring, obstructive uropathy, glomerular diseases (post-infectious GN, nephrotic syndromes), and systemic diseases (SLE) can lead to CKD. Increasing rates of obesity and hypertension in adolescents are shifting the landscape. 

 

 

Environmental and social determinants

 

Delayed or absent access to prenatal care, untreated pediatric infections, exposure to nephrotoxins (some traditional medicines, high-dose NSAIDs), poor nutrition and poverty increase the risk and worsen progression. 

 

 

 

---

 

4. Risk factors for progression of CKD in children

 

Not every child with structural kidney disease will progress rapidly. Important progression-predictors include:

 

Baseline kidney function and proteinuria: Lower GFR and higher proteinuria predict faster decline, as in adults. Proteinuria is both a marker and causal driver of progression. 

 

Hypertension: Uncontrolled blood pressure accelerates kidney injury and causes cardiovascular harm; ambulatory blood pressure monitoring may detect masked hypertension in CKD children. 

 

Recurrent infections / obstruction: Ongoing reflux or obstruction increases scarring and decline.

 

Anemia and CKD-MBD (mineral bone disorder): Severe, untreated metabolic abnormalities contribute to morbidity and may indicate advanced disease. 

 

Socioeconomic barriers: Late referral, poor access to specialty care, and limited resources for dialysis/transplant accelerate progression to ESKD and increase mortality. 

 

 

 

---

 

5. Major complications & risks from pediatric CKD (by system)

 

A. Growth failure and pubertal delay

 

Children with CKD frequently fail to achieve expected height and may experience delayed puberty. Causes are multifactorial: poor nutrition, metabolic acidosis, CKD-MBD, anemia, hormonal dysregulation, and chronic inflammation. Recombinant growth hormone (rhGH) is an evidence-based treatment for selected children after metabolic issues and nutrition are addressed. KDIGO pediatric guidance supports rhGH in appropriately selected cases. Growth impairment has profound lifelong effects on health, social integration and psychosocial wellbeing. 

 

B. Anemia

 

Anemia is common and appears early in pediatric CKD (iron deficiency, reduced erythropoietin production, inflammation). Left untreated it causes fatigue, reduced exercise tolerance, poor school performance, and contributes to cardiovascular strain. KDIGO guidance provides pediatric-relevant diagnostic and treatment pathways (iron repletion, erythropoiesis-stimulating agents). 

 

C. Mineral bone disorder (CKD-MBD)

 

Disordered calcium, phosphate, PTH and vitamin D metabolism leads to rickets-like bone disease in young children, fractures, impaired linear growth, and vascular calcification. CKD-MBD begins early and requires monitoring (phosphate, calcium, PTH, vitamin D) and targeted therapy per KDIGO. Bone disease also contributes to long-term skeletal and cardiovascular risk. 

 

D. Cardiovascular disease (CVD)

 

Children with CKD are at markedly increased risk of premature cardiovascular disease. While symptomatic coronary disease is rare in children, subclinical cardiovascular changes (left ventricular hypertrophy, arterial stiffness, hypertension, endothelial dysfunction) occur early and accumulate as kidney disease progresses — they are the leading cause of death across the lifespan in pediatric CKD. Hypertension, anemia, fluid overload, dyslipidemia, and CKD-MBD all contribute. Early detection (ABPM, echocardiography, vascular stiffness measures) and aggressive management of risk factors are essential. 

 

E. Infections and immune problems

 

Children on dialysis or with advanced CKD have higher infection risk (catheter/vascular access infections, pneumonia, sepsis). Vaccination, infection control and prompt treatment are key. 

 

F. Neurocognitive, educational and psychosocial risks

 

CKD and its treatment (hospitalizations, dialysis) negatively affect neurocognitive development, school attendance, behavior and quality of life. Uremia, anemia, metabolic disturbance and psychosocial stressors all play roles. Early multidisciplinary support (educational planning, psychology) improves outcomes. 

 

G. Nutritional deficits

 

Malnutrition and abnormal body composition are common in pediatric CKD, especially in younger children and pre-dialysis patients. Both undernutrition and obesity (in adolescents) are problems — each with implications for progression and cardiovascular risk. Nutritional monitoring and individualized plans are essential. 

 

 

---

 

6. How CKD in childhood affects long-term life course

 

Children who survive to adulthood carry elevated risks of cardiovascular disease, reduced fertility in some disorders, lower attained height, and ongoing kidney disease that may progress to ESKD later in life. Early CKD also imposes psychosocial and socioeconomic burdens (education, employment). These life-course consequences make early recognition and comprehensive management in childhood a public health priority. 

 

 

 

---

 

7. Diagnosis & monitoring — what to watch for

 

Key monitoring elements (frequency individualized to stage):

 

Kidney function (eGFR) and urine protein/albumin (spot urine albumin-to-creatinine ratio or protein/creatinine ratio).

 

Blood pressure (clinic + ambulatory BP monitoring when available).

 

Growth: height, weight, BMI plotted on appropriate charts; assessment of pubertal stage.

 

Hemoglobin, iron studies; electrolytes, bicarbonate (for metabolic acidosis).

 

Calcium, phosphate, PTH, 25-OH vitamin D (for CKD-MBD).

 

Lipid profile, especially in older children or those with risk factors.

 

Imaging where indicated (renal ultrasound for CAKUT, scarring).

 

Neurodevelopmental screening and psychosocial assessment.

Regular, protocolized surveillance reduces risk of complications and informs timely interventions. KDIGO and pediatric nephrology reviews outline monitoring schedules and thresholds for intervention. 

 

 

 

---

 

8. Prevention and risk-reduction strategies

 

Primary prevention (preventing CKD starting)

 

Improve maternal and perinatal health to reduce prematurity and low birth weight.

 

Prevent and promptly treat pediatric urinary tract infections and congenital obstruction.

 

Avoid unnecessary nephrotoxins in infants/children; regulate access to potentially harmful traditional remedies. 

 

 

Secondary prevention (preventing progression)

 

Early diagnosis and referral to pediatric nephrology.

 

Control blood pressure to pediatric targets (often lower than general pediatric targets for CKD); use ACE inhibitors/ARBs when indicated for proteinuria.

 

Treat anemia and correct metabolic acidosis, optimize nutrition.

 

Manage CKD-MBD proactively (dietary phosphate control, phosphate binders, vitamin D analogues when indicated).

 

Vaccination and infection prevention for immunocompromised or dialysis patients. 

 

 

Tertiary prevention (reduce impact of ESKD)

 

Timely planning for kidney replacement therapy (dialysis access, preemptive transplant where possible). Preemptive living-donor kidney transplant in children has better outcomes than starting dialysis first. 

 

 

 

---

 

9. Special considerations in low-resource settings

 

In many LMICs the key issues are delayed diagnosis, lack of pediatric nephrology services, limited dialysis and transplant availability, and catastrophic out-of-pocket costs. Public health measures — strengthening maternal/child health, training generalists to detect kidney disease early, establishing referral pathways, and disease registries — are critical. Recent global reviews emphasize equity-focused strategies to reduce childhood CKD burden. 

 

 

 

---

 

10. Practical advice for clinicians and families (short checklist)

 

For clinicians

 

Screen at-risk children (CAKUT, prematurity, recurrent UTIs, family history, nephrotoxic exposures) with urine tests and BP.

 

Use age-appropriate BP targets and ABPM to detect masked hypertension. 

 

Treat proteinuria and hypertension proactively (ACEi/ARB).

 

Monitor growth and consider rhGH after addressing nutrition and biochemical abnormalities. 

 

Address anemia, CKD-MBD, acidosis and nutrition per guidelines.

 

Coordinate care: nephrology, dietetics, psychology, social work, and transplant teams as needed. 

 

 

For families

 

Keep routine follow-ups and growth checks; report poor appetite, poor growth, swelling, or changes in urine.

 

Adhere to prescribed medicines (iron, phosphate binders, antihypertensives), and vaccinations.

 

Discuss school planning early — flexibility, catch-up support and communication with teachers help academic progress.

 

Seek support — many centers have family support groups, social workers, and mental-health resources. 

 

 

 

---

 

11. Research gaps and priorities

 

Better global epidemiology data—many recent systematic efforts aim to close this gap. 

 

Interventions to prevent progression in low-resource settings.

 

Long-term studies on cardiovascular prevention starting in childhood.

 

Broader access to genetic testing and tailored therapies for monogenic kidney disease. 

 

 

 

---

 

12. Key takeaways (summary)

 

Pediatric CKD is primarily driven by congenital and genetic disorders, but acquired causes and changing lifestyles (obesity, hypertension) are reshaping the picture. 

 

Children with CKD face multi-system risks: growth failure, bone disease, anemia, infections, neurocognitive and psychosocial impairment, and a high risk of premature cardiovascular disease. Early and repeated surveillance plus multidisciplinary care improves outcomes. 

 

Equity matters: outcomes depend heavily on timely diagnosis, access to pediatric nephrology, dialysis and transplant services, and broader social determinants of health. Public-health and policy responses are needed alongside clinical care. 

 

 

 

---

 

References / Further reading (selected)

 

KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease — 2024 update. 

 

KDIGO 2017 update: CKD-Mineral and Bone Disorder (CKD-MBD). 

 

KDIGO Guideline: Anemia in CKD. 

 

Hsu CN, Pediatric Chronic Kidney Disease: Mind the Gap Between... (MDPI, 2025). 

 

Van Sickle JS et al., Chronic Kidney Disease in Children (2022 review). 

 

Chen WL et al., Cardiovascular Disease Risk in Children With Chronic Kidney Disease (Frontiers in Pediatrics, 2021). 

 

Jung J et al., Mineral bone disorder in children with CKD (2023). 

 

Raina M et al., The global health burden of pediatric chronic kidney disease (PLOS, 2025).